---
document_datetime: 2025-12-29 14:26:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/filsuvez.html
document_name: filsuvez.html
version: success
processing_time: 0.1104342
conversion_datetime: 2025-12-31 01:45:30.206446
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Filsuvez

[RSS](/en/individual-human-medicine.xml/67568)

##### Authorised

This medicine is authorised for use in the European Union

birch bark extract Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Filsuvez](#news-on)
- [More information on Filsuvez](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Filsuvez is a medicine that is used in adults and children aged 6 months or older with epidermolysis bullosa (EB).

EB is an inherited disease of the skin that makes the skin very fragile and causes severe blistering and scarring. Filsuvez is used in two types of EB, dystrophic EB and junctional EB, to treat partial-thickness skin wounds. These are wounds where the upper layers of the skin have been damaged.

EB is rare, and Filsuvez was designated an 'orphan medicine' (a medicine used in rare diseases) on 23 February 2011. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu-310845](/en/medicines/human/orphan-designations/eu-3-10-845)

Filsuvez contains a dry extract from two species of birch bark consisting of naturally occurring substances known as triterpenes, including betulin, betulinic acid, erythrodiol, lupeol and oleanolic acid.

Expand section

Collapse section

## How is Filsuvez used?

Filsuvez is available as a gel that should be applied to the wound surface at a thickness of approximately 1 mm and covered by a wound dressing. The medicine can also be applied directly to the wound dressing. The gel should not be applied sparingly, and should be re-applied with every dressing change until the wound has healed. If symptoms do not improve after use or if wound complications occur, your healthcare professional will assess your condition and consider whether to continue treatment.

For more information about using Filsuvez, see the package leaflet or contact your doctor, nurse or pharmacist.

The medicine can only be obtained with a prescription.

## How does Filsuvez work?

The exact way Filsuvez works is not fully understood. It is thought that the active substance in Filsuvez, birch bark extract, may help the cells that make up the outer layer of the skin (keratinocytes) grow and move towards the gap created by the wound, thereby helping wounds to heal.

## What benefits of Filsuvez have been shown in studies?

The effectiveness of Filsuvez at treating partial-thickness wounds was investigated in one main study involving 223 adults and children with EB, including dystrophic and junctional subtypes. Of those who were treated with Filsuvez in combination with wound dressing, 41% showed complete closure of the wound within 45 days, compared with 29% who were using a control gel (a dummy treatment) in combination with wound dressing. No difference from the control gel was noted after 90 days.

## What are the risks associated with Filsuvez?

The most common side effects with Filsuvez (which may affect more than 1 in 10 people) are wound complications. Other common side effects include skin reactions at the application site, wound infections, pruritis (itching), and hypersensitivity (allergic) reactions (may occur in more than 1 in 100 people).

For the full list of side effects of Filsuvez, see the package leaflet.

## Why is Filsuvez authorised in the EU?

Filsuvez gel was shown to be effective for patients with dystrophic and junctional EB at treating partial-thickness wounds, which can be difficult to heal, leading to pain and a risk of infection, and for which treatment options are limited. Although effects were modest, they were considered clinically meaningful for EB patients with dystrophic and junctional EB and the medicine had an acceptable safety profile, with side effects that were localised and manageable. Therefore, the European Medicines Agency decided that the benefits of Filsuvez are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Filsuvez?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Filsuvez have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Filsuvez are continuously monitored. Suspected side effects reported with Filsuvez are carefully evaluated and any necessary action taken to protect patients.

## Other information about Filsuvez

Filsuvez received a marketing authorisation valid throughout the EU on 21 June 2022.

Filsuvez : EPAR - Medicine Overview

Reference Number: EMA/239723/2022

English (EN) (106.53 KB - PDF)

**First published:** 04/07/2022

[View](/en/documents/overview/filsuvez-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-77)

български (BG) (124.57 KB - PDF)

**First published:**

04/07/2022

[View](/bg/documents/overview/filsuvez-epar-medicine-overview_bg.pdf)

español (ES) (95.5 KB - PDF)

**First published:**

04/07/2022

[View](/es/documents/overview/filsuvez-epar-medicine-overview_es.pdf)

čeština (CS) (120.06 KB - PDF)

**First published:**

04/07/2022

[View](/cs/documents/overview/filsuvez-epar-medicine-overview_cs.pdf)

dansk (DA) (95.07 KB - PDF)

**First published:**

04/07/2022

[View](/da/documents/overview/filsuvez-epar-medicine-overview_da.pdf)

Deutsch (DE) (95.79 KB - PDF)

**First published:**

04/07/2022

[View](/de/documents/overview/filsuvez-epar-medicine-overview_de.pdf)

eesti keel (ET) (94.83 KB - PDF)

**First published:**

04/07/2022

[View](/et/documents/overview/filsuvez-epar-medicine-overview_et.pdf)

ελληνικά (EL) (112.31 KB - PDF)

**First published:**

04/07/2022

[View](/el/documents/overview/filsuvez-epar-medicine-overview_el.pdf)

français (FR) (95.71 KB - PDF)

**First published:**

04/07/2022

[View](/fr/documents/overview/filsuvez-epar-medicine-overview_fr.pdf)

hrvatski (HR) (100.81 KB - PDF)

**First published:**

04/07/2022

[View](/hr/documents/overview/filsuvez-epar-medicine-overview_hr.pdf)

italiano (IT) (95.41 KB - PDF)

**First published:**

04/07/2022

[View](/it/documents/overview/filsuvez-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (119.45 KB - PDF)

**First published:**

04/07/2022

[View](/lv/documents/overview/filsuvez-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (119.19 KB - PDF)

**First published:**

04/07/2022

[View](/lt/documents/overview/filsuvez-epar-medicine-overview_lt.pdf)

magyar (HU) (108.14 KB - PDF)

**First published:**

04/07/2022

[View](/hu/documents/overview/filsuvez-epar-medicine-overview_hu.pdf)

Malti (MT) (114.41 KB - PDF)

**First published:**

04/07/2022

[View](/mt/documents/overview/filsuvez-epar-medicine-overview_mt.pdf)

Nederlands (NL) (95.4 KB - PDF)

**First published:**

04/07/2022

[View](/nl/documents/overview/filsuvez-epar-medicine-overview_nl.pdf)

polski (PL) (121.01 KB - PDF)

**First published:**

04/07/2022

[View](/pl/documents/overview/filsuvez-epar-medicine-overview_pl.pdf)

português (PT) (95.36 KB - PDF)

**First published:**

04/07/2022

[View](/pt/documents/overview/filsuvez-epar-medicine-overview_pt.pdf)

română (RO) (118.45 KB - PDF)

**First published:**

04/07/2022

[View](/ro/documents/overview/filsuvez-epar-medicine-overview_ro.pdf)

slovenčina (SK) (112.11 KB - PDF)

**First published:**

04/07/2022

[View](/sk/documents/overview/filsuvez-epar-medicine-overview_sk.pdf)

slovenščina (SL) (108.54 KB - PDF)

**First published:**

04/07/2022

[View](/sl/documents/overview/filsuvez-epar-medicine-overview_sl.pdf)

Suomi (FI) (95.25 KB - PDF)

**First published:**

04/07/2022

[View](/fi/documents/overview/filsuvez-epar-medicine-overview_fi.pdf)

svenska (SV) (95.03 KB - PDF)

**First published:**

04/07/2022

[View](/sv/documents/overview/filsuvez-epar-medicine-overview_sv.pdf)

Filsuvez : EPAR - Risk management plan

English (EN) (1.19 MB - PDF)

**First published:** 04/07/2022

**Last updated:** 11/07/2025

[View](/en/documents/rmp/filsuvez-epar-risk-management-plan_en.pdf)

## Product information

Filsuvez : EPAR - Product Information

English (EN) (623.26 KB - PDF)

**First published:** 04/07/2022

**Last updated:** 13/02/2024

[View](/en/documents/product-information/filsuvez-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-909)

български (BG) (691.69 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/bg/documents/product-information/filsuvez-epar-product-information_bg.pdf)

español (ES) (630.5 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/es/documents/product-information/filsuvez-epar-product-information_es.pdf)

čeština (CS) (661.55 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/cs/documents/product-information/filsuvez-epar-product-information_cs.pdf)

dansk (DA) (595.09 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

17/07/2025

[View](/da/documents/product-information/filsuvez-epar-product-information_da.pdf)

Deutsch (DE) (631.83 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/de/documents/product-information/filsuvez-epar-product-information_de.pdf)

eesti keel (ET) (616.96 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/et/documents/product-information/filsuvez-epar-product-information_et.pdf)

ελληνικά (EL) (586.28 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/el/documents/product-information/filsuvez-epar-product-information_el.pdf)

français (FR) (639.18 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/fr/documents/product-information/filsuvez-epar-product-information_fr.pdf)

hrvatski (HR) (659.37 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/hr/documents/product-information/filsuvez-epar-product-information_hr.pdf)

íslenska (IS) (621.99 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/is/documents/product-information/filsuvez-epar-product-information_is.pdf)

italiano (IT) (626.58 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/it/documents/product-information/filsuvez-epar-product-information_it.pdf)

latviešu valoda (LV) (674.88 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/lv/documents/product-information/filsuvez-epar-product-information_lv.pdf)

lietuvių kalba (LT) (660.85 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/lt/documents/product-information/filsuvez-epar-product-information_lt.pdf)

magyar (HU) (692.58 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/hu/documents/product-information/filsuvez-epar-product-information_hu.pdf)

Malti (MT) (681.75 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/mt/documents/product-information/filsuvez-epar-product-information_mt.pdf)

Nederlands (NL) (626.28 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/nl/documents/product-information/filsuvez-epar-product-information_nl.pdf)

norsk (NO) (606.13 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/no/documents/product-information/filsuvez-epar-product-information_no.pdf)

polski (PL) (683.06 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/pl/documents/product-information/filsuvez-epar-product-information_pl.pdf)

português (PT) (616.48 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/pt/documents/product-information/filsuvez-epar-product-information_pt.pdf)

română (RO) (667.08 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/ro/documents/product-information/filsuvez-epar-product-information_ro.pdf)

slovenčina (SK) (683.41 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/sk/documents/product-information/filsuvez-epar-product-information_sk.pdf)

slovenščina (SL) (651.59 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/sl/documents/product-information/filsuvez-epar-product-information_sl.pdf)

Suomi (FI) (625.82 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/fi/documents/product-information/filsuvez-epar-product-information_fi.pdf)

svenska (SV) (620.88 KB - PDF)

**First published:**

04/07/2022

**Last updated:**

13/02/2024

[View](/sv/documents/product-information/filsuvez-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000249374 15/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Filsuvez : EPAR - All authorised presentations

English (EN) (98.44 KB - PDF)

**First published:** 04/07/2022

**Last updated:** 12/08/2024

[View](/en/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-800)

български (BG) (133.77 KB - PDF)

**First published:**

12/08/2024

[View](/bg/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_bg.pdf)

español (ES) (73.6 KB - PDF)

**First published:**

12/08/2024

[View](/es/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_es.pdf)

čeština (CS) (113.69 KB - PDF)

**First published:**

12/08/2024

[View](/cs/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (74.11 KB - PDF)

**First published:**

12/08/2024

[View](/da/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (84.38 KB - PDF)

**First published:**

12/08/2024

[View](/de/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (77.93 KB - PDF)

**First published:**

12/08/2024

[View](/et/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (90.8 KB - PDF)

**First published:**

12/08/2024

[View](/el/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_el.pdf)

français (FR) (62.47 KB - PDF)

**First published:**

12/08/2024

[View](/fr/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (141.43 KB - PDF)

**First published:**

12/08/2024

[View](/hr/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (80.48 KB - PDF)

**First published:**

12/08/2024

[View](/is/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_is.pdf)

italiano (IT) (52.54 KB - PDF)

**First published:**

12/08/2024

[View](/it/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (120.64 KB - PDF)

**First published:**

12/08/2024

[View](/lv/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (101.79 KB - PDF)

**First published:**

12/08/2024

[View](/lt/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (137.08 KB - PDF)

**First published:**

12/08/2024

[View](/hu/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (74.49 KB - PDF)

**First published:**

12/08/2024

[View](/mt/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (80.49 KB - PDF)

**First published:**

12/08/2024

[View](/nl/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (53.61 KB - PDF)

**First published:**

12/08/2024

[View](/no/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_no.pdf)

polski (PL) (94.44 KB - PDF)

**First published:**

12/08/2024

[View](/pl/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_pl.pdf)

português (PT) (79.54 KB - PDF)

**First published:**

12/08/2024

[View](/pt/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_pt.pdf)

română (RO) (95.78 KB - PDF)

**First published:**

12/08/2024

[View](/ro/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (98.01 KB - PDF)

**First published:**

12/08/2024

[View](/sk/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (71.61 KB - PDF)

**First published:**

12/08/2024

[View](/sl/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (52.29 KB - PDF)

**First published:**

12/08/2024

[View](/fi/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (78.13 KB - PDF)

**First published:**

12/08/2024

[View](/sv/documents/all-authorised-presentations/filsuvez-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Filsuvez Active substance dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w) International non-proprietary name (INN) or common name birch bark extract Therapeutic area (MeSH)

- Epidermolysis Bullosa Dystrophica
- Epidermolysis Bullosa, Junctional

Anatomical therapeutic chemical (ATC) code D03AX13

### Pharmacotherapeutic group

Preparations for treatment of wounds and ulcers

### Therapeutic indication

Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.

## Authorisation details

EMA product number EMEA/H/C/005035

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Chiesi Farmaceutici S.p.A

Via Palermo 26/A

Opinion adopted 22/04/2022 Marketing authorisation issued 21/06/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Filsuvez: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.63 KB - PDF)

**First published:** 15/05/2025

[View](/en/documents/procedural-steps-after/filsuvez-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Filsuvez: EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (158.54 KB - PDF)

**First published:** 23/01/2023

**Last updated:** 15/05/2025

[View](/en/documents/procedural-steps-after/filsuvez-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Filsuvez : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMA/CHMP/549864/2023

English (EN) (124.94 KB - PDF)

**First published:** 30/01/2024

[View](/en/documents/pip-compliance/filsuvez-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

Filsuvez-H-C-005035-II-0006 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/4657/2024

English (EN) (723.55 KB - PDF)

**First published:** 29/01/2024

[View](/en/documents/variation-report/filsuvez-h-c-005035-ii-0006-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Filsuvez : EPAR - Orphan Maintenance Assessment Report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000070235

English (EN) (257.1 KB - PDF)

**First published:** 04/07/2022

[View](/en/documents/orphan-maintenance-report/filsuvez-epar-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Filsuvez : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/260035/2022

English (EN) (2.59 MB - PDF)

**First published:** 04/07/2022

[View](/en/documents/assessment-report/filsuvez-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Filsuvez

Adopted

Reference Number: EMA/CHMP/188166/2022

English (EN) (92.78 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-filsuvez_en.pdf)

#### News on Filsuvez

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022) 22/04/2022

#### More information on Filsuvez

- [EU/3/10/845 - orphan designation for treatment of epidermolysis bullosa](/en/medicines/human/orphan-designations/eu-3-10-845)
- [EMEA-001299-PIP03-17-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001299-pip03-17-m03)
- [A long-term non-interventional study to assess the incidence of skin malignancies in patients with dystrophic and junctional epidermolysis bullosa receiving treatment with Filsuvez (FOSTER) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000244)

**This page was last updated on** 11/07/2025

## Share this page

[Back to top](#main-content)